# Patient With Tirzepatide-treated Type 2 Diabetes With Difficult Visualization During Esophagogastroduodenoscopy

## TL;DR

A patient with type 2 diabetes treated with tirzepatide had trouble with endoscopic exams due to food residue, but stopping the drug improved visualization.

## Contribution

Reports a case where discontinuing tirzepatide improved endoscopic visualization after prior difficulties.

## Key findings

- A patient experienced inadequate endoscopy visualization due to food residue while on tirzepatide.
- Discontinuing tirzepatide for 2 months allowed successful endoscopy.
- Tirzepatide may interfere with upper gastrointestinal procedures.

## Abstract

Tirzepatide, a dual glucagon-like peptide-1 receptor and gastric inhibitory peptide receptor agonist, is an effective treatment for type 2 diabetes mellitus and obesity, resulting in significant improvements in glycated hemoglobin levels and weight reduction. However, gastrointestinal side effects, including delayed gastric emptying, have been reported. Recently, a case of inadequate visualization during esophagogastroduodenoscopy due to substantial food residues in patients treated with tirzepatide has been reported. This study aims to report a patient who underwent a successful esophagogastroduodenoscopy following a 2-month discontinuation of tirzepatide. Previously, the same patient experienced incomplete esophagogastroduodenoscopies due to excessive food residues despite standard preparation. The findings of this study emphasize the challenges associated with the use of tirzepatide for upper gastrointestinal procedures and suggest that the discontinuation of the drug might be necessary to ensure optimal endoscopic evaluation.